Weight-loss medicines
The approved weight-loss medicines side by side: how much weight people actually lost in the trials, what they cost your stomach, and what happens when you stop. Spoiler: the newer injections lead, and none of them is a course you finish.
Quick answer: In trials, tirzepatide (Mounjaro) led to the most weight loss, about 15–21% of body weight, followed by semaglutide (Wegovy) at about 15%. Older options such as liraglutide, phentermine and orlistat helped less. Gut upsets are the main side effect of the injections, and for most people the weight returns after stopping. Ask your GP which, if any, suits you.
At a glance
- For
- Adults with obesity (BMI 30 or more), or BMI 27 or more with a weight-related condition, alongside diet and activity
- Works
- Average loss in the main trials: tirzepatide 15–21%, semaglutide about 15%, phentermine/topiramate about 9% more than dummy treatment, liraglutide 8%, naltrexone/bupropion about 6%, orlistat a few kilograms. Dummy treatment: about 1–3%
- Cost
- None are on the PBS for weight loss (October 2026). Wegovy is being reconsidered for some people with heart disease and obesity
- Kicks in
- Appetite changes within weeks; most weight loss over 6–18 months
- Taken for
- Long term for most. Phentermine is approved only for short courses (up to 3 months)
- Watch for
- Nausea and gut upsets (injections), racing heart and poor sleep (phentermine), oily leakage (orlistat)
If it’s sold with a before-and-after photo and a countdown timer, it isn’t on this list for a reason.
Brand names
- Tirzepatide: Mounjaro
- Semaglutide 2.4 mg: Wegovy
- Liraglutide 3 mg: generic liraglutide (the Saxenda brand left Australia in December 2025)
- Phentermine: Duromine
- Naltrexone with bupropion: Contrave
- Orlistat: Xenical (pharmacist only, no script needed)
- Phentermine with topiramate: Qsymia (US); not approved as a combination in Australia
How it works
- Gut-hormone copies (tirzepatide, semaglutide, liraglutide): slow the stomach and turn up fullness signals in the brain. See GLP-1 medicines.
- Phentermine: a stimulant that suppresses appetite.
- Naltrexone/bupropion: acts on the brain’s appetite and reward pathways.
- Orlistat: blocks about a third of the fat you eat from being absorbed.
Used for
- Weight management alongside a lower-calorie diet and more activity
- Extra approved uses for some: type 2 diabetes, lowering heart risk (Wegovy), sleep apnoea with obesity (Mounjaro)
Compared
Weight figures are average loss in the main trial, on the medicine versus a dummy treatment. Both groups had diet and activity advice, so the medicine’s effect is on top of lifestyle changes.
- Weekly injectionTirzepatide (Mounjaro)
- How it works
- Copies two gut hormones (GIP and GLP-1)
- How taken
- Weekly injection, dose stepped up every 4 weeks
- Weight loss
- SURMOUNT-1: 15.0–20.9% (by dose) vs 3.1% over 72 weeks
- Common side effects
- Nausea, diarrhoea, vomiting, constipation, less appetite
- Not for
- Pregnancy; medullary thyroid cancer or MEN2. Can make the pill less reliable
- When stopped
- SURMOUNT-4: people switched to dummy injections regained 14% of their weight over the next year; those who continued lost another 5.5%
- Weekly injectionSemaglutide 2.4 mg (Wegovy)
- How it works
- Copies a gut hormone (GLP-1)
- How taken
- Weekly injection, dose stepped up every 4 weeks
- Weight loss
- STEP 1: 14.9% vs 2.4% over 68 weeks
- Common side effects
- Nausea, diarrhoea, vomiting, constipation, gallstones
- Not for
- Pregnancy; medullary thyroid cancer or MEN2
- When stopped
- STEP 1 extension: about two-thirds of the lost weight came back within a year
- Daily injectionLiraglutide 3 mg (generics)
- How it works
- Copies a gut hormone (GLP-1)
- How taken
- Daily injection
- Weight loss
- SCALE: 8.0% vs 2.6% over 56 weeks
- Common side effects
- Nausea, diarrhoea, constipation, vomiting
- Not for
- Pregnancy; medullary thyroid cancer or MEN2
- When stopped
- Weight tends to return, as with the weekly versions
- Daily capsulePhentermine (Duromine)
- How it works
- Stimulant appetite suppressant
- How taken
- One capsule in the morning (not at night: it keeps you awake)
- Weight loss
- Approved only for short courses, so long-term trial data are thin
- Common side effects
- Racing heart, raised blood pressure, poor sleep, restlessness, dry mouth
- Not for
- Heart or blood vessel disease, moderate to severe high blood pressure, overactive thyroid, glaucoma, past drug or alcohol misuse, agitation or some mental health conditions
- When stopped
- Courses are limited to 3 months, then reviewed
- Not approved in AustraliaPhentermine with topiramate (Qsymia)
- How it works
- Stimulant plus an anti-seizure medicine that also reduces appetite
- How taken
- Daily capsule (US). In Australia, sometimes as two separate off-label scripts
- Weight loss
- EQUIP and CONQUER: about 9% more than dummy treatment over 56 weeks at the top dose
- Common side effects
- Tingling, dry mouth, constipation, taste change, mood or concentration problems
- Not for
- Pregnancy (topiramate causes birth defects, so reliable contraception is essential), glaucoma, overactive thyroid, heart disease
- When stopped
- Weight tends to return
- TabletsNaltrexone with bupropion (Contrave)
- How it works
- Acts on the brain’s appetite and reward pathways
- How taken
- Tablets, built up over 4 weeks to 2 tablets twice a day
- Weight loss
- COR-I: about 6.1 kg vs 1.4 kg (roughly 6% vs 1%) over 56 weeks
- Common side effects
- Nausea, constipation, vomiting, headache, dizziness, dry mouth
- Not for
- Seizures, anyone taking opioids (it blocks them), uncontrolled blood pressure, eating disorders, bipolar disorder, pregnancy
- When stopped
- Stopped at 16 weeks if less than 5% of body weight has been lost
- Capsule with mealsOrlistat (Xenical)
- How it works
- Blocks about a third of dietary fat from being absorbed
- How taken
- Capsule with each main meal that contains fat
- Weight loss
- XENDOS: 5.8 kg vs 3.0 kg over 4 years, with 37% fewer new cases of diabetes
- Common side effects
- Oily spotting, wind with discharge, urgent or fatty stools, worse after fatty meals
- Not for
- Long-term gut absorption problems, bile flow problems, pregnancy
- When stopped
- Effects stop when the capsules do
Coming soon (not approved in Australia)
- Not approved in AustraliaSemaglutide 25 mg tablet (Wegovy pill)
- Status
- Approved in the US in December 2025
- Weight loss
- OASIS 4: 16.6% vs 2.7% over 64 weeks, in people who kept taking it
- Not approved in AustraliaOrforglipron (Foundayo)
- Status
- Daily pill, no food or water timing rules. Approved in the US in April 2026; submitted to the TGA
- Weight loss
- ATTAIN-1: up to 11.2% vs 2.1% over 72 weeks
- Not approved anywhereCagriSema (cagrilintide with semaglutide)
- Status
- Weekly injection. US decision expected late 2026
- Weight loss
- REDEFINE 1: 20.4% vs 3.0% over 68 weeks
- Not approved anywhereRetatrutide
- Status
- Weekly injection acting on three hormones. Still in trials
- Weight loss
- TRIUMPH-1: 19.0–28.3% (by dose) over 80 weeks
Save your money
- Weight-loss supplements (garcinia, green tea extract, raspberry ketone, chitosan, glucomannan): little or no effect in good-quality trials. Garcinia and green tea extract have been linked to liver damage.
- HCG injections or drops: no evidence they work and not approved for weight loss. Any loss comes from the 500-calorie diet sold with them.
- Compounded or online “Ozempic”: banned from compounding in Australia since October 2024, and often fake or the wrong dose.
- Lifestyle still matters. Every trial above added medicine on top of diet and activity changes. Protein, strength exercise and sleep help keep muscle and keep weight off.
Side effects
- Injections (tirzepatide, semaglutide, liraglutide): nausea, vomiting, diarrhoea, constipation, reflux, gallstones; rarely pancreatitis.
- Phentermine: racing heart, raised blood pressure, poor sleep, restlessness, dry mouth; rarely heart valve or lung blood pressure problems.
- Naltrexone/bupropion: nausea, constipation, headache, dizziness; rarely seizures or mood changes.
- Topiramate: tingling, poor concentration, mood changes, kidney stones.
- Orlistat: oily leakage and urgency; take a multivitamin at bedtime.
Get help urgently if
- Severe tummy pain that won’t settle, sometimes going through to the back (possible pancreatitis)
- Pain under the right ribs, fever or yellow skin (possible gallstones)
- Chest pain, a racing or irregular heartbeat, fainting or new breathlessness (especially on phentermine)
- A seizure, or new low mood or thoughts of self-harm. In Australia, Lifeline is on 13 11 14
- Swelling of the face or throat, or trouble breathing
Good to know
- Pregnancy: none are used in pregnancy. Topiramate causes birth defects; tirzepatide can make the pill less reliable.
- Muscle: a good share of weight lost is lean tissue. Enough protein and strength exercise help protect it.
- Surgery: tell your team you take a GLP-1 medicine (slower stomach emptying) or naltrexone (blocks opioid pain relief).
- Use only TGA-approved products from a pharmacy.
Support lines
If you or someone else is in danger right now, call your emergency number. To talk to someone, any time:
- Australia: Lifeline 13 11 14 (24/7, or text 0477 13 11 14), Suicide Call Back Service 1300 659 467, Beyond Blue 1300 22 4636, 13YARN 13 92 76 for Aboriginal and Torres Strait Islander people. Emergency: 000.
- Young people in Australia: Kids Helpline 1800 55 1800 (24/7, ages 5 to 25) or headspace (ages 12 to 25).
- New Zealand: call or text 1737. Emergency: 111.
- UK and Ireland: Samaritans 116 123. Emergency: 999 (or 112).
- US and Canada: call or text 988. Emergency: 911.
- Anywhere else: findahelpline.com lists free helplines in more than 100 countries.
Common questions
Which weight-loss medicine works best?
On average, tirzepatide, then semaglutide. In a head-to-head trial, people lost 20.2% of their weight on tirzepatide versus 13.7% on semaglutide over 72 weeks. Results vary a lot from person to person.
Do I have to take weight-loss medicine forever?
For most people, the weight comes back after stopping. In trials, most of the lost weight returned within a year of stopping semaglutide or tirzepatide. They work more like blood pressure medicine than a course of antibiotics.
Are weight-loss injections on the PBS?
Not for weight loss, as of October 2026. Ozempic is PBS-subsidised for type 2 diabetes only. Wegovy is being reconsidered for some people with heart disease and obesity.
Do weight-loss supplements work?
Not in good-quality trials. Garcinia, green tea extract, raspberry ketone and similar products show little or no effect, and some have been linked to liver damage.
How does Plenity compare with Wegovy?
Plenity is a US prescription medical device, not a medicine: capsules of a cellulose-based gel that swells in the stomach to help you feel full. In its 6-month trial, alongside a diet, people lost about 6.4% of body weight versus 4.4% on a dummy treatment. Wegovy (semaglutide) averaged about 15% over 68 weeks versus about 2%. They haven’t been compared head to head, and Plenity isn’t widely available outside the US.
Information only. Not a recommendation or endorsement of any product. Whether a medicine suits you depends on your health and other medicines, so talk to your doctor or pharmacist. In an emergency, call 000 (Australia) or your local emergency number. From a mobile, 112 works in most countries.
More information
- SURMOUNT-1 trial: Tirzepatide for obesity (NEJM)
- SURMOUNT-4 trial: Continuing versus stopping tirzepatide (JAMA)
- STEP 1 trial: Semaglutide for weight management (NEJM)
- STEP 1 extension: Weight regain after stopping semaglutide
- SCALE trial: Liraglutide 3 mg for weight management
- Phentermine/topiramate: EQUIP and CONQUER results
- COR-I trial: Naltrexone/bupropion (The Lancet, 2010)
- XENDOS trial: Orlistat over 4 years
- Duromine (phentermine) product information
- Contrave product information
- Medsafe: Topiramate and pregnancy (2025)
- PBS: Wegovy listing status
- Healio: FDA approves Wegovy pill
- Pharmacy Times: FDA approves orforglipron (April 2026)
- Pharmacy Daily: Orforglipron submitted in Australia
- BioSpace: CagriSema filed with the FDA
- Pharmacy Times: Retatrutide TRIUMPH-1 results (May 2026)
- US National Institutes of Health: Dietary supplements for weight loss
- CBS News: FDA and FTC act on HCG weight-loss products
maladywise.com/medicines/weight-loss-medicines/